Pomalidomida

Resumen

Alternativas con registro en Colombia

• Azatioprina · costo anual estimado $ 500.780
• Talidomide · costo anual estimado $ 1.202.310
• Metotrexate · costo anual estimado $ 4.204.070
• Lenalidomida · costo anual estimado $ 25.996.760
• Pirfenidona · costo anual estimado $ 73.463.550
• Fumarato DE Dimetilo · costo anual estimado $ 25.109.445

Estudios clínicos principales

• CARTITUDE-4: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Da
  Fase 3 · 2020 · 419 participantes · Janssen Research & Development, LLC · NCT04181827
• RESUME: Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
  Fase 3 · 2010 · 267 participantes · Celgene · NCT01178281
• NIMBUS: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-D
  Fase 3 · 2011 · 455 participantes · Celgene · NCT01311687 · PubMed 27173785 · PubMed 24007748
• OPTIMISMM: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  Fase 3 · 2013 · 559 participantes · Celgene · NCT01734928

Enfermedades relacionadas

• VIH
• Cáncer (todos)
• Mieloma múltiple
• Sarcomas y GIST

Fuentes

• Etiqueta FDA (DailyMed): Pomalidomide
• EMA: Pomalidomide Teva
• EMA: Pomalidomide Krka